First Head to Head Study Comparing CRESTOR and LIPITOR®

AstraZenecaAstraZeneca announced the launch of a new clinical trial, SATURN, designed to measure the impact of CRESTOR™ (rosuvastatin) 40 mg and atorvastatin (Lipitor®) 80 mg on the progression of atherosclerosis in high risk patients. SATURN will compare the effects of these two statins on the ability to decrease progression or induce regression of atherosclerosis, the main cause of cardiovascular disease, following two years of treatment in patients with coronary artery disease.

"The impact on atherosclerosis has been studied previously in separate clinical trials involving rosuvastatin and atorvastatin," said Elisabeth Bjork, Global Medical Science Director for CRESTOR, "This study, for the first time, will provide physicians with important information to better understand how these two statins compare when treating dyslipidaemic patients with advanced atherosclerosis."

SATURN, (Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin Versus AtorvastatiN), is a 104-week, parallel-group, multicentre, double-blind, Phase IIIb intravascular ultrasound (IVUS) imaging study of approximately 1,300 patients at 170 centres worldwide. The first patient will be enrolled later this month and the study is expected to complete in 2011. SATURN is part of AstraZeneca’s extensive GALAXY clinical trials programme, designed to address important unanswered questions in statin research and to investigate the impact of rosuvastatin on control of lipids, atherosclerosis and cardiovascular morbidity and mortality. Currently, more than 63,000 patients have been recruited from 55 countries worldwide to participate in the GALAXY Programme.

"Two major studies in the GALAXY programme have already demonstrated the significant impact of rosuvastatin 40mg on atherosclerosis across the disease spectrum. The ASTEROID study was the first to show regression of coronary atherosclerosis in patients with established disease, and the METEOR study showed that rosuvastatin can also slow or delay the progression of carotid atherosclerosis in patients with early signs of the disease. The results of the SATURN study will provide additional information on how best to treat patients with the very serious condition of advanced atherosclerosis," said Elisabeth Bjork. "We believe the data from this study will underscore the benefits of intensively managing cholesterol levels with rosuvastatin, both LDL-C and HDL-C, to reduce the burden of atherosclerosis."

Data from other atherosclerosis trials in the GALAXY programme, METEOR and ASTEROID, have demonstrated that intensive treatment with Rosuvastatin 40mg results in effective lipid management and beneficial effects across the atherosclerotic disease spectrum:

  • METEOR was the first study to show that rosuvastatin demonstrated a positive effect on atherosclerosis in people at low risk of coronary heart disease (CHD) and with early signs of carotid artery disease as measured by B-mode ultrasound.
  • ASTEROID demonstrated that rosuvastatin regressed atherosclerosis as measured by intravascular ultrasound (IVUS) in high risk patients with evidence of coronary artery disease by coronary angiography.

In the U.S., based on the METEOR study, rosuvastatin has been approved as an adjunct to diet to slow the progression of atherosclerosis in patients with elevated cholesterol. The rosuvastatin Prescribing Information in Europe has been updated to incorporate data from the METEOR study.

CRESTOR has now received regulatory approvals in over 90 countries. Over 11 million patients have been prescribed rosuvastatin worldwide. Global sales of CRESTOR for the first nine months of 2007 were $1,997 million - an increase of 30 per cent on the same period of 2006. Data from clinical trials and real world use shows that the safety profile for rosuvastatin is in line with other marketed statins.

The 40 mg dose is the highest registered dose of rosuvastatin. Rosuvastatin should be used according to the prescribing information, which contains recommendations for initiating and titrating therapy according to the individual patient profile. In most countries, the usual recommended starting dose of rosuvastatin is 10mg. The 40mg dose should only be used in patients who have not achieved their LDL-C goal utilising the 20mg dose of rosuvastatin.

About AstraZeneca
AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of $26.47 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4 Good Index.

Most Popular Now

COVID-19 Long-Acting AntiBody (LAAB) combination A…

AstraZeneca's long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside th...

Johnson & Johnson announces European Commissio…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the European Commission (EC), acting on behalf of the European Union (EU) Member States, has approved an Advance Pur...

BioNTech and Pfizer initiate rolling submission to…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lea...

Vir Biotechnology and GSK announce global expansio…

Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Eff...

Johnson & Johnson initiates pivotal global Pha…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, J...

Regeneron's REGN-COV2 antibody cocktail reduced vi…

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cockta...

Gilead Sciences signs joint procurement agreement …

Gilead Sciences (Nasdaq: GILD) and the European Commission signed a joint procurement agreement (JPA) that will enable rapid and equitable access to Veklury® (remdesivir)...

COVID-19 vaccine AZD1222 clinical trial resumed in…

The Phase I/II clinical trial for the COVID-19 vaccine AZD1222 has resumed in Japan after discussion with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). ...

Popular COVID-19 conspiracies linked to vaccine 'h…

A new study of beliefs and attitudes toward COVID-19 in five different countries - UK, US, Ireland, Mexico and Spain - has identified how much traction some prominent con...

Scientists identify common vulnerabilities across …

In a study published online in Science, an international team of almost 200 researchers from 14 leading institutions in six countries, including France with the Institut ...

Sanofi and Translate Bio mRNA COVID-19 vaccine can…

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced...

Potential COVID-19 vaccines not affected by domina…

Vaccines currently being developed for COVID-19 should not be affected by recent mutations in the virus, according to a new study involving a University of York virologis...